IBCL-123 inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)

Laurie H. Sehn,Kai Hubel, Stefano Luminari,Antonio Salar,Bjorn E. Wahlin,Ajay K. Gopal,Christophe Bonnet,Shankara Paneesha,Marek Trneny,Hafsat Mashegu,Christine F. Lihou,Lulu Cheng,Christian W. Scholz

Clinical Lymphoma Myeloma and Leukemia（2022）

Cited 0|Views16

No score

Abstract

Primary endpoint is PFS (investigator-assessed [INV] by Lugano 2014 criteria) for patients with FL. Secondary endpoints include PFS (INV) in the overall population, PET-CR rate (INV) at 90 days after last treatment, and OS in patients with FL.

Translated text

Key words

IBCL,non-Hodgkin lymphoma,CD19,marginal zone lymphoma,follicular lymphoma,Phase III

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined